Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939653 · ClinicalTrials.gov registry record · Phase 2
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
A Phase 2 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00939653 is a Phase 2 study that was terminated before completion, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 6 participants.
The verdict
NCT00939653, a Phase 2 study, was terminated before completion, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs. Clofarabine will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Filgrastim
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-07-10 |
| Est. Completion | 2011-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00939653
The ClinicalTrials.gov registry entry for NCT00939653 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00939653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00939653 about?
NCT00939653 is a clinical study titled "T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)". Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs. Clofarabine will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).
What is the current status of trial NCT00939653?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2009-07-10. Estimated completion is 2011-07-15.
What interventions are being tested in trial NCT00939653?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Filgrastim (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00939653?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.